ERBB2 and breast cancer: Moreover, alterations in all three members of the RAS family, such as the recurrent oncogenic mutations KRASG12D, HRASK117R or amplifications in NRAS, were observed in HR+/HER2− BC that did not respond well to CDK4/6is [46].